Johnson & Johnson (JNJ) Current Assets (2009 - 2026)
Johnson & Johnson's (JNJ) quarterly Current Assets came in at $59.2 billion in Q1 2026, down 17.3% year-on-year from $71.6 billion in Q1 2025, and up 6.38% quarter-over-quarter from $55.6 billion in Q4 2025.
Johnson & Johnson (JNJ) Current Assets (2009 - 2026) Analysis & Trends
Johnson & Johnson has disclosed Current Assets across 18 years of filings, most recently posting $59.2 billion for Q1 2026.
- Current Assets for Q1 2026 came in at $59.2 billion, down 17.3% year-over-year; the trailing twelve-month figure through Mar 2026 was $59.2 billion (down 17.3% YoY), and the FY2025 annual result was $55.6 billion, changed 0.48% from the prior year.
- Current Assets came in at $59.2 billion for Q1 2026 at Johnson & Johnson, up from $55.6 billion in the prior quarter.
- In the past five years, Current Assets ranged from a high of $71.6 billion in Q1 2025 to a low of $53.2 billion in Q3 2024.
- The 5-year median for Current Assets is $57.4 billion (2024), against an average of $58.7 billion.
- Across the five-year window, Current Assets dropped 17.68% in 2023 and gained 25.52% in 2025, its largest moves.
- Johnson & Johnson's Current Assets stood at $65.2 billion in 2022, then fell by 18.0% to $53.5 billion in 2023, then increased by 4.48% to $55.9 billion in 2024, then fell by 0.48% to $55.6 billion in 2025, then grew by 6.38% to $59.2 billion in 2026.
- The last three Current Assets figures came in at $59.2 billion (Q1 2026), $55.6 billion (Q4 2025), and $54.6 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn | 23.94 Bn |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn | 54.84 Bn |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn | 59.17 Bn |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn | 33.53 Bn |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn | 35.02 Bn |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn | 31.48 Bn |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn | 18.64 Bn |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn | 42.82 Bn |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn | 27.21 Bn |
| 10 | Novartis Ag | 108.28 Bn | 107.60 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 29, 2026 | 59.17 Bn |
| Dec 28, 2025 | 55.62 Bn |
| Sep 28, 2025 | 54.61 Bn |
| Jun 29, 2025 | 54.50 Bn |
| Mar 30, 2025 | 71.55 Bn |
| Dec 29, 2024 | 55.89 Bn |
| Sep 29, 2024 | 53.25 Bn |
| Jun 30, 2024 | 57.82 Bn |
| Mar 31, 2024 | 57.00 Bn |
| Dec 31, 2023 | 53.50 Bn |
| Oct 1, 2023 | 53.70 Bn |
| Jul 2, 2023 | 60.57 Bn |
| Apr 2, 2023 | 64.39 Bn |
| Jan 1, 2023 | 55.29 Bn |
| Oct 2, 2022 | 65.24 Bn |
| Jul 3, 2022 | 63.85 Bn |
| Apr 3, 2022 | 60.42 Bn |
| Jan 2, 2022 | 60.98 Bn |
| Oct 3, 2021 | 59.89 Bn |
| Jul 4, 2021 | 53.77 Bn |